Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

By sjmartinez • December 13, 2024

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2024 Dec 9:S2352-3018(24)00247-9. doi: 10.1016/S2352-3018(24)00247-9. Epub ahead of print. PMID: 39667379.

Tags: Infectious Diseases, Publications

Implementation of a One Health Surveillance System in the Democratic Republic of the Congo

Kinzie PR, Lombe B, Merritt S, Halbrook M, Vakaniaki EH, Mukadi P, L'k'ye AM, Mona J, Kanonge D, Mfwangkang M, Witte D, Melofchik C, Muyembe-Tamfum[...]

Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial

Ramaswami R, Nordwall JA, Gilbert D, Kitchell E, Timiryasova A, Mitsuyasu R, Phillips AN, Lundgren J, Grabar S. Early antiretroviral therapy and long-term cancer risk[...]

Kidney abnormalities in young people living with HIV on dolutegravir-based regimens in Kampala, Uganda

Nasuuna EM, Hoffman R, Kalyesubula R, Chikwari CD, Weiss HA. Kidney abnormalities in young people living with HIV on dolutegravir-based regimens in Kampala, Uganda. AIDS[...]